Search | Clinical Trials Finder

Conditions: Breast Carcinoma, Head and Neck Cancer, Lung Cancer
Interventions: Best Practice, Medical Device Usage and Evaluation, Respiratory Muscle Training, Survey Administration; Other · Procedure
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 21 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Drug-Related Side Effects and Adverse Reactions
Interventions: Not listed
Lead sponsor: Cipherome, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 3 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: San Jose, California

Conditions: Cancer
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 9
States / cities: Orange, California • Hartford, Connecticut • Wilmington, Delaware + 6 more

Conditions: Hodgkin Lymphoma, Non Hodgkin Lymphoma, Leukemia, Multiple Myeloma
Interventions: Not listed
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Cardiotoxicity, Breast Cancer, Lymphoma, Sarcoma, Leukemia, Myeloma, Lung Cancer
Interventions: MyoStrain®; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Adverse Events, Pharmacokinetic
Interventions: ABT-143, ABT-335, Rosuvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2008
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Myopia, Hyperopia
Interventions: narafilcon B daily disposable soft contact lenses, etafilcon A daily disposable soft contact lenses; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 8 Years and older
Enrollment: 1,171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 37
States / cities: Campbell, California • Fullerton, California • Huntington Beach, California + 29 more

Conditions: COVID-19
Interventions: Nuvaxovid (NVX-CoV2705), mNEXSPIKE mRNA-1283; Drug
Lead sponsor: Marcel Curlin; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Adverse Drug Reaction
Interventions: Pharmacogenetic Intervention Arm (pharmacogenetic testing); Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 4,465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Stevens-Johnson Syndrome, Graft Versus Host Disease in Eye, Sjogren's Syndrome, Dry Eye
Interventions: Tangible Boost, Placebo; Device · Other
Lead sponsor: Tangible Science; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Needham, Massachusetts

Conditions: Medication Errors
Interventions: Electronic Health Record Implementation; Other
Lead sponsor: Agency for Healthcare Research and Quality (AHRQ); Federal
Eligibility: 18 Years and older
Enrollment: 2,030 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Drug/Agent Toxicity by Tissue/Organ, Leukemia
Interventions: amifostine trihydrate, cytarabine, idarubicin; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2003
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Locally Advanced Unresectable or Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma
Interventions: Telisotuzumab Adizutecan, Budigalimab, Fluorouracil, Leucovorin, Oxaliplatin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 8
States / cities: Duarte, California • Irvine, California • Santa Monica, California + 5 more

Conditions: Crohn's Disease
Interventions: ABBV-154, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 45
States / cities: Dothan, Alabama • Mobile, Alabama • Coronado, California + 38 more

Conditions: Neuralgia, Postherpetic
Interventions: Lamictal in the treatment of Post-Herpetic Neuralgia; Drug
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 85 Years
Timeline: Started 2005
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Transitions of Care, Patient Portals, General Medicine, Discharge Checklist, Patient-provider Communication, Adverse Event, Readmission
Interventions: Interactive Digital Health Tools; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Drug Toxicity
Interventions: HPN-100, HPN-100 or Placebo, Placebo, Moxifloxacin; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 98 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Breast Carcinoma, Head and Neck Carcinoma, Sarcoma
Interventions: Survey, Survey Administration, Telephone-Based Intervention; Other · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions: Carvedilol, Laboratory Biomarker Analysis, Patient Observation; Drug · Other
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 491 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 577
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Hot Springs, Arkansas + 375 more

Conditions: Cancer
Interventions: Methotrexate; Drug
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 1 Year to 22 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: Etentamig, Pomalidomide, Daratumumab, Dexamethasone, Carfilzomib, Teclistamab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 24
States / cities: Tucson, Arizona • Cerritos, California • Los Angeles, California + 19 more

Conditions: Breast Cancer
Interventions: EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 61 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: New York, New York • The Bronx, New York

Conditions: Radiation Necrosis
Interventions: 25% Mannitol, Low-dose Intra-arterial Bevacizumab; Drug
Lead sponsor: Norton Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 2
States / cities: Lexington, Kentucky • Louisville, Kentucky

Conditions: Cancer, Immunotherapy, PD-1, PD-L1, Immune Checkpoint Therapy
Interventions: Not listed
Lead sponsor: Oxford Biodynamics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Norwich, Connecticut • Dublin, Georgia • Rock Hill, South Carolina

Search by objective public record fields.

Home-based Respiratory Muscle Training for Minimizing Side Effects in Patients Undergoing Treatment for Cancer

DOAC ADRs Retrospective Study

Validation Study of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events

PROactive Evaluation of Function to Avoid CardioToxicity

Study to Compare the Bioavailability of ABT-335 and Rosuvastatin From ABT-143 Relative to That From the Co-administration of ABT-335 and Rosuvastatin Calcium

Daily Disposable Performance of 1•DAY ACUVUE® TruEye™ and 1•DAY ACUVUE® MOIST® With LACREON® TECHNOLOGY

COVID-19 Reactogenicity

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

Evaluation of Tangible Boost for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Vs Host Disease

Statewide Implementation of Electronic Health Records

Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease

Lamictal in the Treatment of Post-Herpetic Neuralgia

Interactive Digital Health Tools to Improve Patient Safety in Acute Care

Double-Blind Randomized Crossover Trial to Access Electrocardiogram Effects of HPN-100

Nurse-Driven Telephone Intervention in Improving Side Effects in Cancer Patients Undergoing Chemotherapy

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity

Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

Neuropsychologic and Electrophysiological Features of Cancer-Related Cognitive Side Effects in Racial and Ethnic Minority Breast Cancer Patients

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

A Prospective Real World Evidence Study (PROWES) for Concordance Rate of Blood-based 3D Genome Conformation Mapping (Episwitch CiRT®) to Identify Likelihood of Response and Actual Response Rates to PD-(L)-1 Checkpoint Inhibitors Across Multiple Oncological Indications.